Login to Your Account

Amgen myeloma drug Kyprolis to benefit from surprise EMA rebuff for Takeda's Ninlaro

By Cormac Sheridan
Staff Writer

Tuesday, May 31, 2016

DUBLIN – In one of the most baffling decisions the EMA has made in recent years, the agency's Committee for Human Medicinal Products last week issued a negative opinion in response to Takeda Pharmaceutical Co.'s application for approval of Ninlaro in relapsed or refractory multiple myeloma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription